A lightweight micrograph cross-section displaying cholesterol-containing plaque in a coronary heart artery
NIGEL DOWNER/SCIENCE PHOTO LIBRARY
The prospects for a one-time therapy that reduces the danger of coronary heart illness for the remainder of an individual’s life simply obtained brighter. In an preliminary trial, a single dose of a CRISPR gene-editing remedy lowered cholesterol ranges with none severe unwanted effects.
The “Coronary heart-2” trial – organised by the biotech firm Verve Therapeutics in Boston – concerned 14 individuals who both had an inherited situation resulting in very excessive ldl cholesterol or had developed heart disease at a younger age. Whereas this was an early-stage trial…
